Form 4 for ABBV AbbVie
Accepted 2024-02-06 00:00:00 ET · period of report 2024-02-02 · accession 0001415889-24-002828 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-06 | 2024-02-02 | ABBV | Siatis Perry C | EVP, GC AND Sec | D - Sale to Iss | $170.00 | -2,919 | 10.4K | -22% | -$496.2K |
| D | 2024-02-06 | 2024-02-02 | ABBV | Siatis Perry C | EVP, GC AND Sec | A - Grant | $144.54 | +2,919 | 13.3K | +28% | +$421.9K |
| D | 2024-02-06 | 2024-02-02 | ABBV | Siatis Perry C | EVP, GC AND Sec | M - OptEx | $144.54 | -2,919 | 5,837 | -33% | -$421.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2024-02-02 | D | D | 2,919 | $170.00 | 10,377 | D | — | — | (F1) This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on February 14, 2023. |
| 2 | Common | Common Stock, $0.01 par value | 2024-02-02 | A | A | 2,919 | $144.54 | 13,296 | D | — | — | |
| 3 | Derivative | Option (Right to buy) | 2024-02-02 | M | D | 2,919 | $144.54 | 5,837 | D | $144.54 · 2023-02-17 to 2032-02-16 | 2,919 Common Stock | (F2) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |